[1] KATHAWALA R, GUPTA P, ASHBY C, et al. The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade[J]. Drug Resist Update, 2015, 18:1-17.
[2] ZEINALI S, MAJIDI S, NIKZAMIR N, et al. Magnetic nanoparticles as potential candidates for biomedical and biological applications[J]. Artificial Cells, Nanomed Biotechnol, 2016:1-10.
[3] DUAN J, MANSOUR H, ZHANG Y, et al. Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles[J]. Int J Pharm, 2012, 426(1-2):193-201.
[4] WOLFBEIS O.An overview of nanoparticles commonly used in fluorescent bioimaging[J]. Chem Soc Rev, 2015, 44(14):4743-4768.
[5] WEI T, CHEN C, LIU J, et al. Anticancer drug nanomicelles formed by self-assembling amphiphilic-dendrimer to combat cancer drug resistance[J]. Proc Natl Acad Sci USA, 2015, 112(10):2978-2983.
[6] WANG J, WU L, KOU L, et al. Novel nanostructured enoxaparin sodium-PLGA hybrid carriers overcome tumor multidrug resistance of doxorubicin hydrochloride[J]. Int J Pharm, 2016, 513(1-2):218-226.
[7] CHAO Y, LIANG Y, FANG G, et al. Biodegradable polymersomes as nanocarriers for doxorubicin hydrochloride: enhanced cytotoxicity in MCF-7/ADR cells and prolonged blood circulation[J]. Pharm Res-Dordr, 2017, 34(3):610-618.
[8] WANG Y, HUANG Y, ANREDDY N, et al. Tea nanoparticle, a safe and biocompatible nanocarrier, greatly potentiates the anticancer activity of doxorubicin[J]. Oncotarget, 2016, 7(5):5877-5891.
[9] MIZRAHY S, RAZ S, HASGAARDM, et al. Hyaluronan-coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions and on the immune response[J]. J Controlled Release, 2011, 156(2):231-238.
[10] WANG J, MA W, GUO Q, et al. The effect of dual-functional hyaluronic acid-vitamin E succinate micelles on targeting delivery of doxorubicin[J]. Int J Nanomed, 2016, 11: 5851-5870.
[11] JUNG H, MOK H. Mixed micelles for targeted and efficient doxorubicin delivery to multidrug-resistant breast cancer cells[J]. Macromol Biosci, 2016, 16(5):748-758.
[12] ZHONG Y, ZHANG J, CHENG R, et al. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts[J]. J Controlled Release, 2015, 205: 144-154.
[13] YANG D, WANG T, SU Z, et al. Reversing cancer multidrug resistance in xenograft models via orchestrating multiple actions of functional mesoporous silica nanoparticles[J]. ACS Applmater Inter, 2016, 8(34):22431-22441.
[14] HE Y, XING L, CUI P, et al. Transferrin-inspired vehicles based on pH-responsive coordination bond to combat multidrug-resistant breast cancer[J]. Biomaterials, 2017, 113: 266-278.
[15] ZHU B, ZHANG H, YU L. Novel transferrin modified and doxorubicin loaded Pluronic 85/lipid-polymeric nanoparticles for the treatment of leukemia: in vitro and in vivo therapeutic effect evaluation[J]. Biomed Pharmacother, 2017, 86: 547-554.
[16] FRANZEN S. A comparison of peptide and folate receptor targeting of cancer cells: from single agent to nanoparticle[J]. Expert Opin Drug Deliv, 2011, 8(3):281-298.
[17] HONG W, CHEN D, ZHANG X, et al. Reversing multidrug resistance by intracellular delivery of Pluronic^® P85 unimers[J]. Biomaterials, 2013, 34(37):9602-9614.
[18] WANG H, YIN H, YAN F, et al. Folate-mediated mitochondrial targeting with doxorubicin-polyrotaxane nanoparticles overcomes multidrug resistance[J]. Oncotarget, 2015, 6(5):2827.
[19] EMILIANA P, STEFANIA P, ANNARITA F, et al. Liposome armed with herpes virus-derived gH625 peptide to overcome doxorubicin resistance in lung adenocarcinoma cell lines[J]. Oncotarget, 2015, 7(4):4077-4092.
[20] JIANG D, GAO X, KANG T, et al. Actively targeting D-alpha-tocopheryl polyethylene glycol 1000 succinate-poly(lactic acid) nanoparticles as vesicles for chemo-photodynamic combination therapy of doxorubicin-resistant breast cancer[J]. Nanoscale, 2016, 8(5):3100-3118.
[21] CHEN Y, ZHANG W, HUANG Y, et al. In vivo biodistribution and anti-tumor efficacy evaluation of doxorubicin and paclitaxel-loaded pluronic micelles decorated with c(RGDyK) peptide[J]. PLoS One, 2016, 11(3):e149952.
[22] HAO L, YUAN G, WANG Z.Aptamer: a potential antitumor drugs "targeted ligand"[J]. China Med Herald(中国医药导报), 2012(30):5-6.
[23] LIAO Z, CHUANG E, LIN C, et al. An AS1411 aptamer-conjugated liposomal system containing a bubble-generating agent for tumor-specific chemotherapy that overcomes multidrug resistance[J]. J Controlled Release, 2015, 208: 42-51.
[24] LIU J, WEI T, ZHAO J, et al. Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance[J]. Biomaterials, 2016, 91: 44-56.
[25] TAM Y, TO K, CHOW A.Fabrication of doxorubicin nanoparticles by controlled antisolvent precipitation for enhanced intracellular delivery[J]. Colloid Surface B, 2016, 139: 249-258.
[26] MAO X, SI J, HUANG Q, et al. Self-assembling doxorubicin prodrug forming nanoparticles and effectively reversing drug resistance in vitro and in vivo[J]. Adv Healthc Mater, 2016, 5(19):2517-2527.
[27] YANG L, CAO L, ZHAO T, et al. The progress of multifunctional envelope-type nano device [J]. Acta Pharm Sin (药学学报), 2018,53(1):47-53.
[28] FENG Q, LIU J, LI X, et al. One-step microfluidic synthesis of nanocomplex with tunable rigidity and acid-switchable surface charge for overcoming drug resistance[J]. Small, 2017, 13(9):1603109.
[29] LIU J, MA X, JIU S, et al. Zinc oxide nanoparticles as adjuvant to facilitate doxorubicin intracellular accumulation and visualize pH-responsive release for overcoming drug resistance[J]. Mol Pharm, 2016, 13(5):1723-1730.
[30] TAO X Y, JIA N, CHENG N H, et al. Design and evaluation of a phospholipase D based drug delivery strategy of novel phosphatidyl-prodrug[J]. Biomaterials, 2017, 131:1-14.
[31] SUN W, YANG S, YAN X, et al. Research status of activatable cell-penetrating peptides-modified nanocarrier systems[J]. Chin Pharm J(中国药学杂志), 2015, 50(23):2015-2018.
[32] MURA S, NICOLAS J, COUVREUR P. Stimuli-responsive nanocarriers for drug delivery [J]. Nat Mater, 2013, 12(11):991-1003.
[33] HAN N, ZHAO Q, WAN L, et al. Hybrid lipid-capped mesoporous silica for stimuli-responsive drug release and overcoming multidrug resistance[J]. ACS Appl Mater Inter, 2015, 7(5):3342-3351.
[34] XU H, YANG D, CAI C, et al. Dual-responsive mPEG-PLGA-PGlu hybrid-core nanoparticles with a high drug loading to reverse the multidrug resistance of breast cancer: an in vitro and in vivo evaluation[J]. Acta Biomater, 2015, 16: 156-168.
[35] LIU J, LI Q, ZHANG J, et al. Safe and effective reversal of cancer multidrug resistance using sericin-coated mesoporous silica nanoparticles for lysosome-targeting delivery in mice[J]. Small, 2017, 13(9):1602567.
[36] LIONG M, LU J, KOVOCHICH M, et al. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery[J]. ACS Nano, 2008, 2(5):889-896.
[37] PILAPONG C, KEEREETA Y, MUNKHETKORN S, et al. Enhanced doxorubicin delivery and cytotoxicity in multidrug resistant cancer cells using multifunctional magnetic nanoparticles[J]. Colloid Surface B, 2014, 113: 249-253.
[38] ELUMALAI R, PATIL S, MALIYAKKAL N, et al. Protamine-carboxymethyl cellulose magnetic nanocapsules for enhanced delivery of anticancer drugs against drug resistant cancers[J]. Nanomed-Nanotechnol, 2015, 11(4):969-981.
[39] DENG Z, YAN F, JIN Q, et al. Reversal of multidrug resistance phenotype in human breast cancer cells using doxorubicin-liposome-microbubble complexes assisted by ultrasound[J]. J Controlled Release, 2014, 174: 109-116.
[40] YAO C, WANG P, LI X, et al. Near-infrared-triggered azobenzene-liposome/upconversion nanoparticle hybrid vesicles for remotely controlled drug delivery to overcome cancer multidrug resistance[J]. Adv Mater, 2016, 28(42):9341-9348.
[41] WANG Y, ZHAO R, WANG S, et al. In vivo dual-targeted chemotherapy of drug resistant cancer by rationally designed nanocarrier[J]. Biomaterials, 2016, 75:71-81.
[42] GAO W, YE G, DUAN X, et al. Transferrin receptor-targeted pH-sensitive micellar system for diminution of drug resistance and targetable delivery in multidrug-resistant breast cancer[J]. Int J Nanomed, 2017, 12:1047-1064.
[43] JIA X, ZHANG J, ZHAO T, et al. Research situation of pH low insertion peptides[J]. Acta Pharm Sin(药学学报), 2018, 53(3):375-382.
[44] ZHANG W, WANG F, WANG Y, et al. pH and near-infrared light dual-stimuli responsive drug delivery using DNA-conjugated gold nanorods for effective treatment of multidrug resistant cancer cells[J]. J Controlled Release, 2016, 232: 9-19.
[45] WANG H, ZHAO Y, WANG H, et al. Low-molecular-weight protamine-modified PLGA nanoparticles for overcoming drug-resistant breast cancer[J]. J Controlled Release, 2014, 192: 47-56.
[46] PAN Z, WANG H, ZHANG M, et al. Nuclear-targeting TAT-PEG-Asp8-doxorubicin polymeric nanoassemblyto overcome drug-resistant colon cancer[J]. Acta Pharmacol Sin(中国药理学报), 2016, 37(8):1110-1120.
[47] WANG M, HAN M, LI Y, et al. Chemosensitization of doxorubicin in multidrug-resistant cells by unimolecular micelles via increased cellular accumulation and apoptosis[J]. J Pharmacol, 2016, 68(3):333-341.
[48] TRAN T, NGUYEN H, PHAM T, et al. Development of a graphene oxide nanocarrier for dual-drug chemo-phototherapy to overcome drug resistance in cancer[J]. ACS Applmater Inter, 2015, 7(51):28647-28655.
[49] PAI C, CHEN Y, HSU C, et al. Carbon nanotube-mediated photothermal disruption of endosomes/lysosomes reverses doxorubicin resistance in MCF-7/ADR cells[J]. J Biomed Nanotechnol, 2016, 12(4):619-629.
[50] TIAN G, ZHANG X, ZHENG X, et al. Multifunctional Rbx WO3 nanorods for simultaneous combined chemo-photothermal therapy and photoacoustic/CT imaging[J]. Small, 2014,10(20):4160-4170.
[51] REN Y, WANG R, LIU Y, et al. A hematoporphyrin-based delivery system for drug resistance reversal and tumor ablation[J]. Biomaterials, 2014, 35(8):2462-2470.
[52] WILLIAMS J, BUCHANAN C, PITT W. Codelivery of doxorubicin and verapamil for treating multidrug resistant cancer dells[J]. Pharm Nanotechnol, 2018, 6(2):1-8.
[53] CAO S, YIN T, YANG S. Reversing effects of curcumin on multi-drug resistance of Bel7402/5-fu cell line[J]. Chin J Integr Tradit Chin West Med(中国中西医结合),2012, 32(2):244-247,252.
[54] LV L, QIU K, YU X, et al. Amphiphilic copolymeric micelles for doxorubicin and curcumin co-delivery to reverse multidrug resistance in breast cancer[J]. J Biomed Nanotechnol, 2016, 12(5):973-985.
[55] MA W, GUO Q, LI Y, et al. Co-assembly of doxorubicin and curcumin targeted micelles for synergistic delivery and improving anti-tumor efficacy[J]. Eur J Pharm Biopharm, 2017, 112: 209-223.
[56] GU Y, LI J, LI Y, et al. Nanomicelles loaded with doxorubicin and curcumin for alleviating multidrug resistance in lung cancer[J]. Int J Nanomed, 2016, 11: 5757-5770.
[57] DANG S, LI G, LIU M. Research progress on quercetin in reversing tumor multidrug resistance[J]. China Cancer(中国肿瘤), 2017, 26(10):802-807.
[58] DAGLIOGLU C.Enhancing tumor cell response to multidrug resistance with pH-sensitive quercetin and doxorubicin conjugated multifunctional nanoparticles[J]. Colloid Surface B, 2017, 156: 175-185.
[59] ZHANG C, YANG S, ZHU W, et al. Distinctive polymer micelle designed for siRNA delivery and reversal of MDR1 gene-dependent multidrug resistance[J]. J Biomed Mater Res B, 2017, 105(7):2093-2106.
[60] SUN L, WANG D, CHEN Y, et al. Core-shell hierarchical mesostructured silica nanoparticles for gene/chemo-synergetic stepwise therapy of multidrug-resistant cancer[J]. Biomaterials, 2017, 133: 219-228.
[61] FAN Y, LIAO J, LU Y, et al. MiR-375 and doxorubicin co-delivered by liposomes for combination therapy of hepatocellular carcinoma[J]. Mol Ther-Nucl Acids, 2017, 7: 181-189.
[62] FLOREA A, BUSSELBERG D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects[J]. Cancers, 2011, 3(1):1351-1371.
[63] ZHANG X, LI J, YAN M.Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin[J]. Drug Dev Ind Pharm, 2016, 42(10):1590-1599.
[64] MIAO L, GUO S, LIN C, et al. Nanoformulations for combination or cascade anticancer therapy[J]. Adv Drug Deliv Rev, 2017, 115: 3-22.